Smoking Objective of 'Healthy People 2000' Is Probably Not Attainable

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

WASHINGTON--The US Public Health Service's 10-year plan for improving Americans' health, dubbed Healthy People 2000, will be a disappointment to antismoking forces. The goal--to decrease the number of smokers to only 15% of the population--will not be reached, and it is likely that 20% of Americans will still be smoking by the end of the century. "We're talking about a lot of people who are going to die," said Harold Freeman, MD, chairman of the President's Cancer Panel.

WASHINGTON--The US Public Health Service's 10-year plan for improvingAmericans' health, dubbed Healthy People 2000, will be a disappointmentto antismoking forces. The goal--to decrease the number of smokersto only 15% of the population--will not be reached, and it islikely that 20% of Americans will still be smoking by the endof the century. "We're talking about a lot of people whoare going to die," said Harold Freeman, MD, chairman of thePresident's Cancer Panel.

Currently, 80 clinical trials are underway in which gene therapyis being used to treat genetic diseases, AIDS, and several typesof cancer. The newly issued patent will cover most of these trials.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
Related Content